How many drugs treat Parkinsonism?

Drug Landscape tracks 10 marketed treatments for Parkinsonism (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/parkinsonism.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Parkinsonism — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Parkinsonism (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Parkinsonism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Sinemet Cr	CARBIDOPA	Aton	Aromatic Amino Acid [EPC]	Lysine-specific demethylase 4E	1975-01-01
Inbrija	LEVODOPA	Merz	Aromatic Amino Acid [EPC]	Tyrosine-protein kinase Fyn	1970-01-01
Gocovri	AMANTADINE	Endo	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1	1968-01-01
Akineton	BIPERIDEN	AbbVie	Anticholinergic	Muscarinic acetylcholine receptor M1	1959-01-01
GOCOVRI	GOCOVRI	Oregon Health and Science University	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1
Amantadin	Amantadin	Centre Hospitalier Universitaire de Nice		Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor
pergolid	pergolid	University Hospital Muenster		5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor
Metixen	metixene	Novartis	metixene	5-hydroxytryptamine receptor 2C
Cogentin	Cogentin	University of Southern California		5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B
Lodosyn	Lodosyn	University of Miami		Lysine-specific demethylase 4E, Aromatic-L-amino-acid decarboxylase, Tyrosine-protein kinase Fyn

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Parkinsonism
AbbVie · 1 drug in Parkinsonism
Aton · 1 drug in Parkinsonism
Centre Hospitalier Universitaire de Nice · 1 drug in Parkinsonism
Endo · 1 drug in Parkinsonism
Merz · 1 drug in Parkinsonism
Novartis · 1 drug in Parkinsonism
Oregon Health and Science University · 1 drug in Parkinsonism
University Hospital Muenster · 1 drug in Parkinsonism
University of Miami · 1 drug in Parkinsonism
University of Southern California · 1 drug in Parkinsonism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Parkinsonism:

Cite this brief

Drug Landscape (2026). Parkinsonism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/parkinsonism. Accessed 2026-06-10.

Parkinsonism full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing